Monocyte Activation Test (MAT)
for Radiopharmaceuticals.
Product-specific MAT feasibility for Radiopharmaceuticals.
CUP Contract Labs is currently preparing a dedicated MAT setup for radiopharmaceutical and complex injectable products.
The Monocyte-activation test, or MAT, supports human-cell-based pyrogen testing according to Ph. Eur. 2.6.30 using an in vitro approach.
For radiopharmaceuticals, however, a standard MAT is not sufficient — especially when endotoxins and non-endotoxin pyrogens must be assessed under real radioactive sample constraints. Radionuclide, activity level, formulation, sample volume, decay profile and the narrow time window between production and test initiation may influence the meaningfulness of the test result.
That is why we are developing a structured approach for product-specific feasibility assessment, method adaptation and validation planning under radioactive sample constraints.
Final regulatory notification is planned for August. Early technical discussions, project assessments and feasibility planning are already possible.
From Project Request
to MAT strategy.
Eight steps toward a robust MAT concept.
Our planned MAT workflow follows a clear, product-specific approach. The objective is not only to perform a test. The objective is a robust concept that is scientifically meaningful, operationally realistic, GMP-relevant in its documentation and suitable for regulatory discussion.
For radiopharmaceuticals, product matrix, radionuclide, activity level, sample volume, timing, radiation protection and validation objective must be considered at an early stage. This helps identify method-related risks before validation or regulatory discussions become time-critical.
You provide product information, development phase, intended test purpose and available sample details. This information forms the basis for the first technical assessment.
We review radionuclide, activity level, formulation, sample volume, matrix composition and timing. This creates a clear picture of the product-specific framework conditions.
We evaluate potential interferences, radiation-related requirements, dilution options and handling. The objective is a realistic assessment of whether MAT can be meaningfully implemented under the given conditions.
We develop a product-specific MAT concept including assay format, controls, sample preparation and acceptance criteria. The study design is aligned with the product, development phase and intended use of the results.
The MAT setup is adapted to the product matrix and radioactive sample workflow. Sample preparation, dilution strategy, controls and readout are specifically aligned with the product.
Interference, spike recovery, reproducibility and suitability are assessed according to the intended use. The validation scope may vary depending on the development phase and regulatory expectations.
Results are documented in a structured study report. This can support development, QA review and regulatory discussion.
Depending on project status, the method can support development studies, comparability work or future QC strategies. The objective is a MAT concept that is not only scientifically sound, but also practically implementable.
expert voices
For radiopharmaceuticals, it is not enough to ask whether a product can generally be tested. The key question is whether the test result remains scientifically meaningful under real radioactive sample constraints.
WHITEPAPER
Monocyte Activation Test for Radiopharmaceuticals.
Scientific background for your MAT strategy.
How can the Monocyte Activation Test be meaningfully transferred to radiopharmaceutical products? Our whitepaper explains the scientific background, regulatory requirements, typical feasibility questions and the structured CUP workflow for MAT projects under radioactive sample constraints.
Would you like to discuss a specific product or validation strategy directly? We can help you assess at an early stage which technical and regulatory questions are relevant for your MAT project.
Frequently asked questions
about MAT planning for radiopharmaceuticals.
The dedicated MAT setup for radiopharmaceutical and complex injectable products is currently in preparation. Final regulatory notification is planned for August. Early technical discussions, project assessments and feasibility planning are already possible.
Radiopharmaceuticals can differ significantly from conventional parenteral products. Radionuclide, activity level, formulation, sample volume, decay profile and timing may influence cell viability, cytokine readout, dilution strategy and MAT interpretation.
We can already discuss product matrix, radioactive sample constraints, potential interferences, intended use, development phase, validation scope, sample logistics and documentation requirements. This helps define a realistic MAT strategy at an early stage.
At CUP, the focus is not only on performing a test. The key question is whether MAT can generate scientifically meaningful results under the real conditions of a radiopharmaceutical product. This is particularly relevant when validation, QA review or regulatory discussions need to be prepared.
Clarify your MAT strategy
early.
For radiopharmaceuticals in development, method adaptation or regulatory preparation.
CUP supports you in the phase in which validation has not yet started, but the key decisions are being made:
- Is MAT suitable for your product?
- Which interferences can be expected?
- Which sample conditions are realistic?
- And how can a test concept be developed that can later be validated?
This creates an early MAT strategy for radiopharmaceutical and complex injectable products that is scientifically meaningful, operationally realistic and suitable for regulatory discussion.